Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells
Markus D. Siegelin, Takehiko Dohi, Christopher M. Raskett, Gregory M. Orlowski, Christine M. Powers, Candace A. Gilbert, Alonzo H. Ross, Janet Plescia, Dario C. Altieri
Markus D. Siegelin, Takehiko Dohi, Christopher M. Raskett, Gregory M. Orlowski, Christine M. Powers, Candace A. Gilbert, Alonzo H. Ross, Janet Plescia, Dario C. Altieri
View: Text | PDF
Research Article Oncology

Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells

  • Text
  • PDF
Abstract

Fine tuning of the protein folding environment in subcellular organelles, such as mitochondria, is important for adaptive homeostasis and may participate in human diseases, but the regulators of this process are still largely elusive. Here, we have shown that selective targeting of heat shock protein-90 (Hsp90) chaperones in mitochondria of human tumor cells triggered compensatory autophagy and an organelle unfolded protein response (UPR) centered on upregulation of CCAAT enhancer binding protein (C/EBP) transcription factors. In turn, this transcriptional UPR repressed NF-κB–dependent gene expression, enhanced tumor cell apoptosis initiated by death receptor ligation, and inhibited intracranial glioblastoma growth in mice without detectable toxicity. These data reveal what we believe to be a novel role of Hsp90 chaperones in the regulation of the protein-folding environment in mitochondria of tumor cells. Disabling this general adaptive pathway could potentially be used in treatment of genetically heterogeneous human tumors.

Authors

Markus D. Siegelin, Takehiko Dohi, Christopher M. Raskett, Gregory M. Orlowski, Christine M. Powers, Candace A. Gilbert, Alonzo H. Ross, Janet Plescia, Dario C. Altieri

×

Figure 3

Mitochondrial Hsp90 regulates autophagy.

Options: View larger image (or click on image) Download as PowerPoint
Mitochondrial Hsp90 regulates autophagy.
(A–C) LN229 cells were treated ...
(A–C) LN229 cells were treated with G-TPP and analyzed by EM (A and B) or immunoelectron microscopy with an antibody to COX-IV (C). Arrowheads, COX-IV–reactive material. Scale bars: 2 μm (A); 1 μm (B); 200 nm (C). (D) U87 cells were treated with G-TPP, harvested at the indicated time intervals, and analyzed by immunoblotting. The position of the unmodified (I) or lipidated (II) form of LC3 is indicated. (E) U251 cells were transfected with LC3-GFP, treated with vehicle or G-TPP, and analyzed after 16 hours by fluorescence microscopy (left). The percentage of cells with punctate GFP fluorescence was quantified (right). Mean ± SD of 4–6 independent microscopy fields. (F) U87 cells were incubated with inhibitors of phagosome formation, bafilomycin A (BF), or 3-methyladenine (3-MA) for 1 hour, treated with G-TPP, and analyzed after 16 hours by MTT. Mean ± SD of replicates. (G) L229 cells were transfected with control or atg5-directed siRNA and analyzed by immunoblotting. (H) siRNA-transfected LN229 cells as in G were analyzed for cell viability after 16 hours by MTT. Mean ± SD of replicates.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts